-
1
-
-
33749854572
-
High-throughput screening: Update on practices and success
-
DOI 10.1177/1087057106292473
-
S. Fox, S. Farr-Jones, L. Sopchak, A. Boggs, H.W. Nicely, and R. Khoury High-throughput screening: update on practices and success J Biomol Screen 11 2006 864 869 (Pubitemid 44562328)
-
(2006)
Journal of Biomolecular Screening
, vol.11
, Issue.7
, pp. 864-869
-
-
Fox, S.1
Farr-Jones, S.2
Sopchak, L.3
Boggs, A.4
Nicely, H.W.5
Khoury, R.6
Biros, M.7
-
2
-
-
17044373269
-
Finding the target after screening the phenotype
-
C.P. Hart Finding the target after screening the phenotype Drug Discov Today 10 2005 513 519
-
(2005)
Drug Discov Today
, vol.10
, pp. 513-519
-
-
Hart, C.P.1
-
3
-
-
0000356151
-
A nonclonogenic cytotoxicity assay using primary cultures of patient tumor cells for anticancer drug screening
-
S. Dhar, J. Gullbo, K. Nilsson, P. Nygren, and R. Larsson A nonclonogenic cytotoxicity assay using primary cultures of patient tumor cells for anticancer drug screening J Biomol Screen 3 1998 207 215
-
(1998)
J Biomol Screen
, vol.3
, pp. 207-215
-
-
Dhar, S.1
Gullbo, J.2
Nilsson, K.3
Nygren, P.4
Larsson, R.5
-
4
-
-
77949957365
-
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
-
S.V. Sharma, D.A. Haber, and J. Settleman Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents Nat Rev Cancer 10 2010 241 253
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 241-253
-
-
Sharma, S.V.1
Haber, D.A.2
Settleman, J.3
-
5
-
-
59149093636
-
Chemosensitivity and chemoresistance testing in ovarian cancer
-
I.A. Cree Chemosensitivity and chemoresistance testing in ovarian cancer Curr Opin Obstet Gynecol 21 2009 39 43
-
(2009)
Curr Opin Obstet Gynecol
, vol.21
, pp. 39-43
-
-
Cree, I.A.1
-
6
-
-
67749139054
-
Predictive tests for individualization of pharmacological cancer treatment
-
P. Nygren, and R. Larsson Predictive tests for individualization of pharmacological cancer treatment Expert Opin Med Diagn 2 2008 1 12
-
(2008)
Expert Opin Med Diagn
, vol.2
, pp. 1-12
-
-
Nygren, P.1
Larsson, R.2
-
7
-
-
0033105697
-
Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic
-
DOI 10.1016/S0959-8049(98)00286-X, PII S095980499800286X
-
H. Fridborg, E. Jonsson, P. Nygren, and R. Larsson Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic Eur J Cancer 35 1999 424 432 (Pubitemid 29151940)
-
(1999)
European Journal of Cancer
, vol.35
, Issue.3
, pp. 424-432
-
-
Fridborg, H.1
Jonsson, E.2
Nygren, P.3
Larsson, R.4
-
8
-
-
33845304732
-
Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients
-
DOI 10.1016/j.bcp.2006.08.016, PII S0006295206005284
-
M. Wickstrom, K. Danielsson, L. Rickardson, J. Gullbo, P. Nygren, and A. Isaksson Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients Biochem Pharmacol 73 2007 25 33 (Pubitemid 44872876)
-
(2007)
Biochemical Pharmacology
, vol.73
, Issue.1
, pp. 25-33
-
-
Wickstrom, M.1
Danielsson, K.2
Rickardson, L.3
Gullbo, J.4
Nygren, P.5
Isaksson, A.6
Larsson, R.7
Lovborg, H.8
-
9
-
-
42549086712
-
The novel alkylating prodrug J1: Diagnosis directed activity profile ex vivo and combination analyses in vitro
-
DOI 10.1007/s10637-007-9092-1
-
M. Wickstrom, C. Haglund, H. Lindman, P. Nygren, R. Larsson, and J. Gullbo The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro Invest New Drugs 26 2008 195 204 (Pubitemid 351579681)
-
(2008)
Investigational New Drugs
, vol.26
, Issue.3
, pp. 195-204
-
-
Wickstrom, M.1
Haglund, C.2
Lindman, H.3
Nygren, P.4
Larsson, R.5
Gullbo, J.6
-
10
-
-
0021883048
-
Application of a human tumor colony-forming assay to new drug screening
-
R.H. Shoemaker, M.K. Wolpert-DeFilippes, D.H. Kern, M.M. Lieber, R.W. Makuch, and N.R. Melnick Application of a human tumor colony-forming assay to new drug screening Cancer Res 45 1985 2145 2153 (Pubitemid 15024321)
-
(1985)
Cancer Research
, vol.45
, Issue.5
, pp. 2145-2153
-
-
Shoemaker, R.H.1
Wolpert-DeFilippes, M.K.2
Kern, D.H.3
-
11
-
-
77955069305
-
High-throughput screening of natural products for cancer therapy
-
Harvey AL, Cree IA. High-throughput screening of natural products for cancer therapy. Planta Med 76:1080-6.
-
Planta Med
, vol.76
, pp. 1080-1086
-
-
Harvey, A.L.1
Cree, I.A.2
-
12
-
-
77955275498
-
Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue
-
Cree IA, Glaysher S, Harvey AL. Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol 10:375-9.
-
Curr Opin Pharmacol
, vol.10
, pp. 375-379
-
-
Cree, I.A.1
Glaysher, S.2
Harvey, A.L.3
-
13
-
-
1842336815
-
In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA)
-
DOI 10.1002/(SICI)1097-0215(19970917)72:6<1008::AID-IJC15>3.0.CO;2- 0
-
K. Csoka, B. Tholander, E. Gerdin, M. de la Torre, R. Larsson, and P. Nygren In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA) Int J Cancer 72 1997 1008 1012 (Pubitemid 27433566)
-
(1997)
International Journal of Cancer
, vol.72
, Issue.6
, pp. 1008-1012
-
-
Csoka, K.1
Tholander, B.2
Gerdin, E.3
De La Torre, M.4
Larsson, R.5
Nygren, P.6
-
14
-
-
0026529184
-
Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA)
-
R. Larsson, J. Kristensen, C. Sandberg, and P. Nygren Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA) Int J Cancer 50 1992 177 185
-
(1992)
Int J Cancer
, vol.50
, pp. 177-185
-
-
Larsson, R.1
Kristensen, J.2
Sandberg, C.3
Nygren, P.4
-
15
-
-
0028059914
-
Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA)
-
DOI 10.1006/gyno.1994.1187
-
K. Csoka, R. Larsson, B. Tholander, E. Gerdin, M. de la Torre, and P. Nygren Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA) Gynecol Oncol 54 1994 163 170 (Pubitemid 24256464)
-
(1994)
Gynecologic Oncology
, vol.54
, Issue.2
, pp. 163-170
-
-
Csoka, K.1
Larsson, R.2
Tholander, B.3
Gerdin, E.4
De La Torre, M.5
Nygren, P.6
-
16
-
-
50349098488
-
The fluorometric microculture cytotoxicity assay
-
E. Lindhagen, P. Nygren, and R. Larsson The fluorometric microculture cytotoxicity assay Nat Protoc 3 2008 1364 1369
-
(2008)
Nat Protoc
, vol.3
, pp. 1364-1369
-
-
Lindhagen, E.1
Nygren, P.2
Larsson, R.3
-
17
-
-
33749335282
-
The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease
-
DOI 10.1126/science.1132939
-
J. Lamb, E.D. Crawford, D. Peck, J.W. Modell, I.C. Blat, and M.J. Wrobel The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease Science 313 2006 1929 1935 (Pubitemid 44497995)
-
(2006)
Science
, vol.313
, Issue.5795
, pp. 1929-1935
-
-
Lamb, J.1
Crawford, E.D.2
Peck, D.3
Modell, J.W.4
Blat, I.C.5
Wrobel, M.J.6
Lerner, J.7
Brunet, J.-P.8
Subramanian, A.9
Ross, K.N.10
Reich, M.11
Hieronymus, H.12
Wei, G.13
Armstrong, S.A.14
Haggarty, S.J.15
Clemons, P.A.16
Wei, R.17
Carr, S.A.18
Lander, E.S.19
Golub, T.R.20
more..
-
18
-
-
0031947571
-
A simple and sensitive ribonucleotide reductase assay
-
A.Y. Jong, K. Yu, B. Zhou, T. Frgala, C.P. Reynolds, and Y. Yen A simple and sensitive ribonucleotide reductase assay J Biomed Sci 5 1998 62 68 (Pubitemid 28150200)
-
(1998)
Journal of Biomedical Science
, vol.5
, Issue.1
, pp. 62-68
-
-
Jong, A.Y.1
Yu, K.2
Zhou, B.3
Frgala, T.4
Reynolds, P.5
Yen, Y.6
-
19
-
-
18044370285
-
Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model
-
DOI 10.1016/j.ejps.2005.02.006
-
L.E. Friberg, S.B. Hassan, E. Lindhagen, R. Larsson, and M.O. Karlsson Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model Eur J Pharm Sci 25 2005 163 173 (Pubitemid 40602206)
-
(2005)
European Journal of Pharmaceutical Sciences
, vol.25
, Issue.1
, pp. 163-173
-
-
Friberg, L.E.1
Hassan, S.B.2
Lindhagen, E.3
Larsson, R.4
Karlsson, M.O.5
-
20
-
-
0033653660
-
Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats
-
E. Jonsson, L.E. Friberg, M.O. Karlsson, S.B. Hassan, A. Freijs, and K. Hansen Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats Cancer Chemother Pharmacol 46 2000 493 500
-
(2000)
Cancer Chemother Pharmacol
, vol.46
, pp. 493-500
-
-
Jonsson, E.1
Friberg, L.E.2
Karlsson, M.O.3
Hassan, S.B.4
Freijs, A.5
Hansen, K.6
-
21
-
-
0023792919
-
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines
-
D.A. Scudiero, R.H. Shoemaker, K.D. Paull, A. Monks, S. Tierney, and T.H. Nofziger Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines Cancer Res 48 1988 4827 4833
-
(1988)
Cancer Res
, vol.48
, pp. 4827-4833
-
-
Scudiero, D.A.1
Shoemaker, R.H.2
Paull, K.D.3
Monks, A.4
Tierney, S.5
Nofziger, T.H.6
-
22
-
-
8844264615
-
A flexible data analysis tool for chemical genetic screens
-
DOI 10.1016/j.chembiol.2004.08.026, PII S1074552104002790
-
B.P. Kelley, M.R. Lunn, D.E. Root, S.P. Flaherty, A.M. Martino, and B.R. Stockwell A flexible data analysis tool for chemical genetic screens Chem Biol 11 2004 1495 1503 (Pubitemid 39527276)
-
(2004)
Chemistry and Biology
, vol.11
, Issue.11
, pp. 1495-1503
-
-
Kelley, B.P.1
Lunn, M.R.2
Root, D.E.3
Flaherty, S.P.4
Martino, A.M.5
Stockwell, B.R.6
-
23
-
-
0033003760
-
A simple statistical parameter for use in evaluation and validation of high throughput screening assays
-
DOI 10.1177/108705719900400206
-
J.H. Zhang, T.D. Chung, and K.R. Oldenburg A simple statistical parameter for use in evaluation and validation of high throughput screening assays J Biomol Screen 4 1999 67 73 (Pubitemid 29278954)
-
(1999)
Journal of Biomolecular Screening
, vol.4
, Issue.2
, pp. 67-73
-
-
Zhang, J.-H.1
Chung, T.D.Y.2
Oldenburg, K.R.3
-
24
-
-
54249090796
-
Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia
-
E. Lindhagen, A. Eriksson, M. Wickstrom, K. Danielsson, B. Grundmark, and R. Henriksson Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia Eur J Haematol 81 2008 344 353
-
(2008)
Eur J Haematol
, vol.81
, pp. 344-353
-
-
Lindhagen, E.1
Eriksson, A.2
Wickstrom, M.3
Danielsson, K.4
Grundmark, B.5
Henriksson, R.6
-
25
-
-
70449466605
-
Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells
-
Y. Eberhard, S.P. McDermott, X. Wang, M. Gronda, A. Venugopal, and T.E. Wood Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells Blood 114 2009 3064 3073
-
(2009)
Blood
, vol.114
, pp. 3064-3073
-
-
Eberhard, Y.1
McDermott, S.P.2
Wang, X.3
Gronda, M.4
Venugopal, A.5
Wood, T.E.6
-
26
-
-
67349137868
-
Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents
-
D.R. Richardson, D.S. Kalinowski, S. Lau, P.J. Jansson, and D.B. Lovejoy Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents Biochim Biophys Acta 1790 2009 702 717
-
(2009)
Biochim Biophys Acta
, vol.1790
, pp. 702-717
-
-
Richardson, D.R.1
Kalinowski, D.S.2
Lau, S.3
Jansson, P.J.4
Lovejoy, D.B.5
-
27
-
-
64549140743
-
Two-step spin-transition iron(III) compound with a wide [High Spin-Low Spin] plateau
-
J. Tang, J. Costa, S. Smulders, G. Molnár, A. Bousseksou, and S. Teat Two-step spin-transition iron(III) compound with a wide [High Spin-Low Spin] plateau Inorg Chem 48 2009 2128 2135
-
(2009)
Inorg Chem
, vol.48
, pp. 2128-2135
-
-
Tang, J.1
Costa, J.2
Smulders, S.3
Molnár, G.4
Bousseksou, A.5
Teat, S.6
-
28
-
-
62749153738
-
Human cancer cell lines: Experimental models for cancer cells in situ? for cancer stem cells?
-
W.C. van Staveren, D.Y. Solis, A. Hebrant, V. Detours, J.E. Dumont, and C. Maenhaut Human cancer cell lines: experimental models for cancer cells in situ? For cancer stem cells? Biochim Biophys Acta 1795 2009 92 103
-
(2009)
Biochim Biophys Acta
, vol.1795
, pp. 92-103
-
-
Van Staveren, W.C.1
Solis, D.Y.2
Hebrant, A.3
Detours, V.4
Dumont, J.E.5
Maenhaut, C.6
-
29
-
-
33748467107
-
Screening of an annotated compound library for drug activity in a resistant myeloma cell line
-
DOI 10.1007/s00280-006-0216-7
-
L. Rickardson, M. Fryknas, C. Haglund, H. Lovborg, P. Nygren, and M.G. Gustafsson Screening of an annotated compound library for drug activity in a resistant myeloma cell line Cancer Chemother Pharmacol 58 2006 749 758 (Pubitemid 44351254)
-
(2006)
Cancer Chemotherapy and Pharmacology
, vol.58
, Issue.6
, pp. 749-758
-
-
Rickardson, L.1
Fryknas, M.2
Haglund, C.3
Lovborg, H.4
Nygren, P.5
Gustafsson, M.G.6
Isaksson, A.7
Larsson, R.8
-
31
-
-
0141566685
-
Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models
-
T. Voskoglou-Nomikos, J.L. Pater, and L. Seymour Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models Clin Cancer Res 9 2003 4227 4239 (Pubitemid 37204044)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.11
, pp. 4227-4239
-
-
Voskoglou-Nomikos, T.1
Pater, J.L.2
Seymour, L.3
-
32
-
-
1942518907
-
The hollow fibre model in cancer drug screening: The NCI experience
-
DOI 10.1016/j.ejca.2003.11.029, PII S0959804904000115
-
S. Decker, M. Hollingshead, C.A. Bonomi, J.P. Carter, and E.A. Sausville The hollow fibre model in cancer drug screening: the NCI experience Eur J Cancer 40 2004 821 826 (Pubitemid 38519760)
-
(2004)
European Journal of Cancer
, vol.40
, Issue.6
, pp. 821-826
-
-
Decker, S.1
Hollingshead, M.2
Bonomi, C.A.3
Carter, J.P.4
Sausville, E.A.5
-
33
-
-
34250778335
-
Future of toxicology - Iron chelators and differing modes of action and toxicity: The changing face of iron chelation therapy
-
DOI 10.1021/tx700039c
-
D.S. Kalinowski, and D.R. Richardson Future of toxicology - iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy Chem Res Toxicol 20 2007 715 720 (Pubitemid 46953677)
-
(2007)
Chemical Research in Toxicology
, vol.20
, Issue.5
, pp. 715-720
-
-
Kalinowski, D.S.1
Richardson, D.R.2
-
34
-
-
33745823841
-
Ribonucleotide reductase inhibitors and future drug design
-
DOI 10.2174/156800906777723949
-
J. Shao, B. Zhou, B. Chu, and Y. Yen Ribonucleotide reductase inhibitors and future drug design Curr Cancer Drug Targets 6 2006 409 431 (Pubitemid 44033390)
-
(2006)
Current Cancer Drug Targets
, vol.6
, Issue.5
, pp. 409-431
-
-
Shao, J.1
Zhou, B.2
Chu, B.3
Yen, Y.4
-
35
-
-
0014962872
-
Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas
-
H.L. Elford, M. Freese, E. Passamani, and H.P. Morris Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas J Biol Chem 245 1970 5228 5233
-
(1970)
J Biol Chem
, vol.245
, pp. 5228-5233
-
-
Elford, H.L.1
Freese, M.2
Passamani, E.3
Morris, H.P.4
-
36
-
-
33751169387
-
Hypoxia-inducible factor-1 (HIF-1)
-
Q. Ke, and M. Costa Hypoxia-inducible factor-1 (HIF-1) Mol Pharmacol 70 2006 1469 1480
-
(2006)
Mol Pharmacol
, vol.70
, pp. 1469-1480
-
-
Ke, Q.1
Costa, M.2
-
37
-
-
0036897079
-
A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines
-
T.W. Chong, L.D. Horwitz, J.W. Moore, H.M. Sowter, and A.L. Harris A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines Cancer Res 62 2002 6924 6927 (Pubitemid 35424082)
-
(2002)
Cancer Research
, vol.62
, Issue.23
, pp. 6924-6927
-
-
Wen Chong, T.1
Horwitz, L.D.2
Moore, J.W.3
Sowter, H.M.4
Harris, A.L.5
-
38
-
-
50849085751
-
The iron-regulated metastasis suppressor. Ndrg-1: Identification of novel molecular targets
-
Z. Kovacevic, D. Fu, and D.R. Richardson The iron-regulated metastasis suppressor. Ndrg-1: identification of novel molecular targets Biochim Biophys Acta 1783 2008 1981 1992
-
(2008)
Biochim Biophys Acta
, vol.1783
, pp. 1981-1992
-
-
Kovacevic, Z.1
Fu, D.2
Richardson, D.R.3
-
39
-
-
34247373460
-
Iron chelation regulates cyclin D1 expression via the proteasome: A link to iron deficiency-mediated growth suppression
-
DOI 10.1182/blood-2006-10-047753
-
E. Nurtjahja-Tjendraputra, D. Fu, J.M. Phang, and D.R. Richardson Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression Blood 109 2007 4045 4054 (Pubitemid 46641760)
-
(2007)
Blood
, vol.109
, Issue.9
, pp. 4045-4054
-
-
Nurtjahja-Tjendraputra, E.1
Fu, D.2
Phang, J.M.3
Richardson, D.R.4
-
40
-
-
34548286520
-
Tuning cell cycle regulation with an iron key
-
Y. Yu, Z. Kovacevic, and D.R. Richardson Tuning cell cycle regulation with an iron key Cell Cycle 6 2007 1982 1994 (Pubitemid 47327885)
-
(2007)
Cell Cycle
, vol.6
, Issue.16
, pp. 1982-1994
-
-
Yu, Y.1
Kovacevic, Z.2
Richardson, D.R.3
-
41
-
-
0029066979
-
Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: Preliminary results. Italian Neuroblastoma Cooperative Group
-
A. Donfrancesco, B. De Bernardi, M. Carli, A. Mancini, M. Nigro, and L. De Sio Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group Eur J Cancer 31A 1995 612 615
-
(1995)
Eur J Cancer
, vol.31
, pp. 612-615
-
-
Donfrancesco, A.1
De Bernardi, B.2
Carli, M.3
Mancini, A.4
Nigro, M.5
De Sio, L.6
-
42
-
-
0025126032
-
Effects of a single course of deferoxamine in neuroblastoma patients
-
A. Donfrancesco, G. Deb, C. Dominici, D. Pileggi, M.A. Castello, and L. Helson Effects of a single course of deferoxamine in neuroblastoma patients Cancer Res 50 1990 4929 4930 (Pubitemid 20257912)
-
(1990)
Cancer Research
, vol.50
, Issue.16
, pp. 4929-4930
-
-
Donfrancesco, A.1
Deb, G.2
Dominici, C.3
Pileggi, D.4
Castello, M.A.5
Helson, L.6
-
43
-
-
0037237032
-
Examination of the antiproliferative activity of iron chelators: Multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311
-
T.B. Chaston, D.B. Lovejoy, R.N. Watts, and D.R. Richardson Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311 Clin Cancer Res 9 2003 402 414 (Pubitemid 36109758)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.1
, pp. 402-414
-
-
Chaston, T.B.1
Lovejoy, D.B.2
Watts, R.N.3
Richardson, D.R.4
-
44
-
-
0033975268
-
Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity
-
DOI 10.1016/S0006-2952(99)00419-0, PII S0006295299004190
-
R.A. Finch, M. Liu, S.P. Grill, W.C. Rose, R. Loomis, and K.M. Vasquez Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity Biochem Pharmacol 59 2000 983 991 (Pubitemid 30110814)
-
(2000)
Biochemical Pharmacology
, vol.59
, Issue.8
, pp. 983-991
-
-
Finch, R.A.1
Liu, M.-C.2
Grill, S.P.3
Rose, W.C.4
Loomis, R.5
Vasquez, K.M.6
Cheng, Y.-C.7
Sartorelli, A.C.8
-
45
-
-
33645473324
-
A Ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase
-
J. Shao, B. Zhou, A.J. Di Bilio, L. Zhu, T. Wang, and C. Qi A Ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase Mol Cancer Ther 5 2006 586 592
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 586-592
-
-
Shao, J.1
Zhou, B.2
Di Bilio, A.J.3
Zhu, L.4
Wang, T.5
Qi, C.6
|